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The cyclooxygenase (COX) enzyme system is the major pathway catalyzing the
conversion of arachidonic acid into prostaglandins (PGs). PGs are lipid mediators
implicated in a variety of physiological and pathophysiological processes in the
kidney, including renal hemodynamics, body water and sodium balance, and the
inﬂammatory injury characteristic in multiple renal diseases. Since the beginning of
1990s, it has been conﬁrmed that COX exists in 2 isoforms, referred to as COX-1 and
COX-2. Even though the 2 enzymes are similar in size and structure, COX-1 and COX-
2 are regulated by different systems and have different functional roles. This review
summarizes the current data on renal expression of the 2 COX isoforms and high-
lights mainly the role of COX-2 and PGE2 in several physiological and pathophysi-
ological processes in the kidney.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier Ltd. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostaglandins (PGs) are important lipid mediators of
numerous physiological and pathophysiological processes in
the kidney. During normal physiological conditions, PGs play an
essential role in the regulation of renal hemodynamic, renin
release, as well as water and salt balance [1e3]. Likewise,
PG synthesis can be stimulated in response to distinct patho-
physiological situations, including inﬂammation, pain, and
cancer [4,5]. PGs are derived from enzymatic metabolism of
free arachidonic acid to PGG2 and subsequently to PGH2 fol-
lowed by the production of the bioactive PGsdPGE2, PGI2,
PGD2, PGF2adand thromboxane A2 by tissue-speciﬁc syn-
thases (Fig. 1) [6,7]. Cyclooxygenase (COX) is the rate-limiting
enzyme that is responsible for the ﬁrst 2 steps in theical Medicine, Aarhus
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iety of Nephrology. Published
y-nc-nd/4.0/).synthesis of PGs. The COX enzyme exists in 2 isoforms, COX-1
and COX-2. These 2 isoforms have a comparable molecular
mass of 71 and 73 kDa, respectively, but their expression and
distribution within the renal tissue are different. COX-1 is
constitutively expressed at high levels maintaining normal
housekeeping functions. COX-2 is expressed at low levels in the
kidney under normal physiological conditions and is highly
induced in response to inﬂammation and renal injury [1,6]. In
this review, we will highlight mainly the role of COX-2 and
PGE2 in several physiological and pathophysiological processes
in the kidney.Physiologic conditions
COX-1 and COX-2 in the kidney
The differential expression and distribution of the 2 COX
isoforms implicate them as being involved in the regulation of
various physiological functions within the kidney (Fig. 2 ). COX-
1 is the dominant isoform to be expressed in glomerularby Elsevier Ltd. This is an open access article under the CC BY-NC-ND
Figure 1. COX pathway of arachidonic acid metabolism. COX-1 or COX-2
converts arachidonic acid to PGG2 and furthermore to PGH2 via COX and
peroxidase activity. PGH2 is next metabolized to 5 major bioactive pros-
tanoidsdPGE2, PGI2, PGD2, PGF2, and TXA2dthrough their respective
tissue-speciﬁc synthases.
COX, cyclooxygenase; PG, prostaglandin; TX, thromboxane.
Nørregaard et al / COX-2 and PGE2 in the kidney 195mesangial cells, arteriolar endothelial cells, as well as in cortical
and medullary collecting ducts in the kidney of bovine, rabbit,
guinea pig, rat, and mouse [8,9]. In the human kidney, COX-1
has been identiﬁed in the collecting duct cells, interstitial
cells, and vasa recta [10,11]. In contrast, basal COX-2 expression
is less intense and displays some interspecies variation in
localization. COX-2 distribution has been localized in the
macula densa of the cortical thick ascending limb of Henle and
interstitial cells in rodents, rabbit, and dogs [8,12,13]. COX-2
immunoreactivity has also been described in intercalated
cells of the cortical collecting ducts in mouse kidney sectionsFigure 2. Distribution of COX isoforms throughout the nephron. COX-1 (g
medullary interstitial cells. COX-2 (blue) is expressed in the glomerulus, macul
COX, cyclooxygenase.[14]. In humans, COX-2 is associated with parts of the renal
vasculature, loop of Henle, and podocytes [10,11]. Furthermore,
COX-2 has been detected in macula densa in humans >60 years
of age [15]. In general, regarding COX-2 distribution, it is
important to be aware that the previously reported expression
of COX-2 has only been reported during normal physiological
conditions. In response to inﬂammatory states, however, COX-2
may be expressed in many more cells and different cell types
within the kidney [16].
COX-deﬁcient mouse models have provided important in-
formation regarding the role of COX-2. Additional investigation
into the physiological and pathophysiological effects of these 2
isoforms has also been acquired from COX-deﬁcient mice.
Importantly, mice disrupted for COX-1 appear to be generally
healthy, and there are no obvious renal defects [17]. In contrast,
mice with gene disruption of COX-2 have severe nephropathy,
and the kidneys appear pale and smaller than those of thewild-
type littermates. In the earlier states, the kidneys show small
immature glomeruli in the subcapsular region with enlarged
glomeruli outside of this hypoplastic area. With age, the renal
pathology develops into more severe states and results in end-
stage renal disease [18e20]. In addition, gender differences in
renal phenotype have been reported in COX-2edisrupted mice
with a male propensity for kidney injury, increased baseline
water turnover, and hypertension [21,22]. Taken together, it
appears that the COX-2 isoform plays a more dominant role in
the kidney diseases compared with COX-1.PGE2 in the kidney
Although PG production occurs in all tissues, the kidney is a
rich source, particularly with PGE2 being the major renal PG
metabolite. PGE2 can be generated by all renal cells which are
characterized by the presence of PGE2 synthasesdthe enzymereen) is constitutively expressed in the glomerulus, collecting duct, and
a densa, thick ascending limb, and medullary interstitial cells.
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types of PGE2 synthases have been identiﬁed in the kidney,
including microsomal PGE synthase 1 (mPGES-1), mPGES-2,
and cytosolic PGES (cPGES). The expression of mPGES-1 is
inducible in response to physiological or pathophysiological
stimuli and is themost abundant renal PGES form that has been
considered to be functionally coupled to both COX-1 and COX-2
activity to increase the production of PGE2 [23]. In contrast,
mPGES-2 and cPGES expression is constitutive rather than
regulatory, which suggests that these PGESs may be house-
keeping genes involved in both early and late phases of PGE2
production [23,24]. Furthermore, mice deﬁcient in mPGES-1,
but not in mPGES-2 or cPGES, suppress PGE2 synthesis, indi-
cating that mPGES-1 may represent an important renal
pathway responsible for PGE2 production [25e27]. In addition,
studies have demonstrated reduced inﬂammatory response in
mPGES-1edeﬁcient mice, providing evidence that mPGES-1
plays a pivotal role in the production of PGE2 linked to
inﬂammation [28,29].
PGE2 plays an important role in modulating the effect of
vasopressin on the osmotic water reabsorption in the renal
collecting duct cells where it attenuates antidiuretic action.
This effect has been attributed to both inhibition of cAMP
synthesis and elevation of cytosolic calcium (Ca2þ) in rabbit
cortical collecting ducts [30,31] and rat terminal inner medul-
lary collecting ducts causing decreased trafﬁcking of aquaporin
2 (AQP2) to the apical plasma membrane [32,33]. In addition,
the signaling pathways underlying the diuretic effect of PGE2
include the cAMP and Ca2þ-independent activation of the Rho-
kinase and formation of F-actin [34].
The involvement of PGE2 in the regulation of body water
metabolismwas also demonstrated by the association between
the urinary PGE2 excretion and urine concentration [35,36]. In
nephrogenic diabetes insipidus (NDI), patients have severe
polyuria and urinary concentrating impairment in the presence
of normal or high plasma levels of arginine vasopressin (AVP),
and urinary excretion of PGE2 is also increased [35,36]. In an
animal study of lithium-induced NDI, the 24-hour urinary
excretion of PGE2 was also signiﬁcantly increased [37]. These
observations have led to the use of COX inhibitors to concen-
trate urine and decrease urine volume in NDI patients [38e40].
In contrast, urinary PGE2 excretion is decreased in patients
with central diabetes insipidus and can be increased by AVP
treatment in parallel with increased urinary concentrating
ability [36]. Similarly, PGE2 concentration in kidney tissueTable 1. Regulation of COX-2 in response to renal disorders and drugs
Increased COX-2 expression
Obstructive nephropathy
Acute kidney injury
Renal transplantation
Chronic kidney disease
Hypertension
Diabetes mellitus
Lithium nephrotoxicity
Renal artery stenosis
Glomerular diseases
Nephrotic syndrome
Heymann and lupus nephritis
Bartter's syndrome
Loop diuretics
Congestive heart failure
COX, cyclooxygenase; NOS, nitric oxide synthase.slices from congenitally AVP-deﬁcient Brattleboro rats is low
and can be increased in response to V2 receptor agonist 1-
desamino-8-D-arginine vasopressin (dDAVP) treatment [41].
The biological actions of PGE2 are exerted by the activation
of 4 G-proteinecoupled prostanoid receptors, designated EP1,
EP2, EP3, and EP4 [42]. Through these receptors, PGE2 plays a
variety of renal physiological roles, including tubular water and
sodium transport, glomerular ﬁltration, as well as vascular
resistance [43,44]. EP1 stimulates intracellular Ca2þ and con-
tributes to the natriuretic and diuretic effects of PGE2 [45,46] as
well as plays an important role in regulation of the blood
pressure [47]. The EP2 and EP4 receptors activate adenylate
cyclase and increase cAMP production, whereas the EP3 re-
ceptor inhibits cAMP signaling [42]. EP2 and EP4 can increase
water reabsorption via different intracellular signaling path-
ways [48], whereas EP3 decreases water permeability leading
to increased water excretion [46]. PGE2 or the EP1/3 agonist,
sulprostone, decreases vasopressin-induced osmotic water
permeability and AQP2membrane trafﬁcking without affecting
cAMP levels or AQP2 phosphorylation at Ser256 (protein kinase
A phosphorylation consensus site) [41,49]. In a recent review,
Olesen and Fenton [50] provided a detailed information about
the collecting duct water permeability, highlighting the action
of PGE2 and EP receptors. Although PGE2 attenuates the AVP-
mediated urine concentration, a number of unanswered ques-
tions still remain regarding the role of PGE2 in body water
homeostasis.
Pathophysiological conditions
COX-2 and PGE2 has been demonstrated to play key roles in
the pathophysiology of a variety of renal disorders (Table 1).
This section focuses on 2 major renal diseasesdnamely
obstructive nephropathy and acute kidney injury (AKI).
COX-2 and PGE2 in obstructive nephropathy
Obstructive nephropathy is one of the most common kidney
diseases, which may result in serious consequences for kidney
function. Obstructive nephropathy is characterized by the
impairment of most renal function. Initially, renal blood ﬂow
and glomerular ﬁltration rate (GFR) are reduced, and in parallel,
most tubular functions become impaired leading to severe re-
ductions in the ability to handle sodium and water along the
nephron. The molecular explanation for this is severeDecreased COX-2 expression
Neuronal NOS inhibitor: macula densa COX-2
Lithium nephrotoxicity: medullary interstitial cell COX-2
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porters, and AQPwater channels [51]. The consequences are the
development of a severe urinary concentrating defect. In the
more chronic phase of obstruction, renal tissue is characterized
by progressive inﬂammation and development of tubulointer-
stitial ﬁbrosis. There are numerous causes, including kidney
stones, cancer of the prostate, and congenital malformations,
contributing to the obstructive nephropathy [52].
The PG system is activated in response to obstructive ne-
phropathy, and several studies have demonstrated that ureteral
obstruction is associated with a marked induction of COX-2 and
increased PGs and thromboxane synthesis [12,53e61]. Pharma-
cological intervention for the treatment of obstructive ne-
phropathy has been focused on different approaches, including
thehemodynamicdysregulation, alteredwaterand salt handling,
and the development of inﬂammation and tubulointerstitial
ﬁbrosis. The role of PGs and thromboxane in the dysregulation of
hemodynamic parameters is complex as these lipid mediators
are a mixture of both vasoconstrictors and vasodilators. Speciﬁc
blocking of the vasoconstrictor thromboxane further attenuates
the reducedGFR in response to obstructive nephropathy, butGFR
is unchanged when PG production is nonselectively inhibited by
the COX inhibitor indomethacin [62].
Several studies have investigated the role of PGs on altered
water and salt handling in obstructive nephropathy. It has been
described that pharmacological inhibition of COX-2 prevents
increased PGE2 production as well as the downregulation of
renal water channels and sodium transporters in response to
acute bilateral ureteral obstruction [12,56]. In addition, we have
demonstrated that disruption of COX-2 prevents down-
regulation of the expression of the water channel protein AQP2
and AQP3 in the cortex of the mice subjected to bilateral ure-
teral obstruction [54]. In the postobstructive kidney, COX-2
inhibition attenuates the downregulation of AQP2 and re-
duces polyuria acutely after the release of obstruction [55,60].
Thus, the data indicate that the increased COX-2emediated
PGE2 synthesis plays an important role for the dysregulation of
renal AQPs and sodium transporters, which contributes to the
impaired urinary concentrating capacity in response to
obstructive nephropathy.
The PG system is similarly an important pharmacological
target for the prevention of renal inﬂammation and ﬁbrosis.
Studies have shown that selective COX-2 inhibition ameliorates
the progression of renal parenchymal damage and interstitial
ﬁbrosis caused by unilateral ureteral obstruction (UUO) [63,64].
In addition, we have inhibited COX-2 using a chitosan nano-
particle system delivering antieCOX-2 small interfering RNA
(siRNA) that targets COX-2 in only macrophages. These parti-
cles have been administrated by intraperitoneal injection, and
the nature of the chitosan nanoparticles and the macrophage-
rich environment in the peritoneum provide avid uptake into
macrophages, and these macrophages are then recruited to the
obstructed kidney. The results demonstrated that siRNA
knockdown of COX-2 prevents or minimizes renal damage,
inﬂammation, and apoptosis in a UUO model, placing RNA
interference (RNAi) as a new potential therapeutic in COX-2
inhibition [58]. Likewise, it has recently been observed that
antioxidants can inhibit the induction of COX-2 in renal med-
ullary interstitial cells in response to UUO, suggesting that
reactive oxygen species/oxidative stress might play a role in the
regulation of the COX-2emediated progression of renal damage
and inﬂammation [57].Finally, the PGE2/EP4 receptors have been revealed as po-
tential pharmacological targets in obstructive nephropathy.
EP4 receptor can affect injurious responses, and Nakagawa et al
[65] have demonstrated that EP4 can also limit the progression
of tubulointerstitial ﬁbrosis by suppressing the inﬂammatory
response in response to UUO.
COX-2 and PGE2 response in AKI
AKI represents an acute reduction in renal function and a
change in the structure that can lead to increasedmorbidity and
mortality in critically ill patients [66]. Previous studies
demonstrated that experimental AKI induced by complete
obstruction of the renal arteries followed by reperfusion in rats
revealed structural alterations in renal tubule epithelia in
association with impaired urinary concentrating ability and
sodium excretion [67,68]. The impairment of urinary concen-
tration was associated with signiﬁcantly decreased expression
of AQPs in the kidney collecting duct as well as in the proximal
tubule [67]. Such an experimental model with complete renal
artery occlusion followed by reperfusion only partlymimics AKI
in human patients. More than 70% of AKI in humans is of
circulatory nature and results from hypoxic injury to the kidney,
including hypovolemia or hemorrhagic shock [69].
COX inhibitors, including both nonsteroidal anti-
inﬂammatory drugs (NSAIDs) and selective COX-2 inhibitors,
have been associated with an increased risk of AKI [70]. AKI
could be complicated in the setting of NSAID therapy, particu-
larly in the clinical situations of decreased effective circulating
volume, including chronic kidney disease, congestive heart
failure, and liver cirrhosis. Under these circumstances, a fall in
effective circulating volume leads to activation of the
renineangiotensin and adrenergic nervous system, which re-
sults in renal vasoconstriction and impaired renal function. This
will stimulate endogenous renal synthesis of vasodilatory PGs
to antagonize the vasoconstriction and normalize renal perfu-
sion and GFR. Therefore, an inhibition of these PG-dependent
counterregulatory mechanisms will disrupt the balance be-
tween vasoconstriction and vasodilation and potentially give
rise to AKI [71e73].
The application ofNSAIDs or COX-2 inhibitors inpatientswith
high-risk factors of AKI might be dependent on dose and dura-
tion of treatment, and drugs should be used with caution to
reduce AKI occurrence. Huerta et al [70] demonstrated an
increased risk of AKI with long-term therapy and high dose of
NSAIDs compared with low-medium dose. Furthermore, they
did not ﬁnd a greater risk at the beginning of NSAID treatment.
Therefore, is short-term and low-dose application of COX in-
hibitors associatedwith increased AKI incidence? In some forms
of AKI, COX inhibitors have revealed beneﬁcial roles in animal
models. Studies have demonstrated that indomethacin, which is
one of themost widely used NSAIDs in clinics, attenuates severe
dysfunction as well as renal inﬂammation and ﬁbrosis after
ischemia/reperfusion (I/R)einduced AKI in rodents [74e78].
Furthermore, it has recently been shown that the protective ef-
fects of indomethacin are highly dose dependent in mice sub-
jected to I/R injury [74]. Likewise, studies have reported that
speciﬁc COX-2 blockade can minimize the progression of renal
damage and oxidative stress in cisplatin- and I/R-induced AKI
[77,79]. In addition, recent studies have shown that COX-2 in-
hibition can prevent oxidative injury in response to renal I/R in a
dose-dependent manner [80,81]. In contrast, other studies have
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hibitors or COX-2 knockoutmice increases renal dysfunction and
injury after renal I/R [82,83]. Ranganathan et al [84] also
demonstrated that COX-2emediated PGE2 production exacer-
bates I/R-induced injury via the EP4 receptor. The inconsistency
between the various studies may be due to different experi-
mental strategies such as different animal species and I/Rmodels
with different duration of ischemia or reperfusion time aswell as
selection of different COX-2 inhibitors. The results of COX-2
disruption could be different according to the different types of
AKI, possibly due to the diversity of the pathogenicmechanisms.
Taken together, the effects of NSAIDs or selective COX-2 in-
hibitors may be dependent on the various pathophysiological
mechanisms and insults related to kidney disorders.Conclusion
This review has provided evidence that the COX-2ederived
PGs are implicated in a variety of physiological and patho-
physiological processes in the kidney. During normal physio-
logical conditions, PGs play important roles in the regulation of
renal hemodynamic and homeostasis of body water and so-
dium balance. In addition, COX-2 and PGs are involved in
different pathophysiological conditions, including obstructive
nephropathy and AKI. The role of COX-2 and COX-2 inhibitors in
numerous pathophysiological conditions still remains contro-
versial as detrimental versus beneﬁcial effects of COX-2 occur
and may depend on the underlying pathophysiological condi-
tions. This reveals a counterbalanced intrarenal handling of
COX-2 highlighting the importance of the enzyme in renal
physiology.Conﬂicts of interest
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